Amarin Corporation PLC (AMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amarin Corporation PLC (AMRN) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.39 Million) by net assets ($449.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Amarin Corporation PLC (AMRN) strategic asset index to assess the company's strategic physical and investment asset allocation.
Amarin Corporation PLC - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Amarin Corporation PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. See AMRN total equity for net asset value and shareholders' equity analysis.
Amarin Corporation PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amarin Corporation PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baiyang Aquatic Group Inc
SHE:002696
|
0.003x |
|
Artesian Resources Corporation
NASDAQ:ARTNA
|
0.041x |
|
Anhui Chaoyue Environmental Protection Technology Co. Ltd.
SHE:301049
|
N/A |
|
Beetaloo Energy Australia Limited
AU:BTL
|
-0.117x |
|
Polaris Media
OL:POL
|
0.072x |
|
Anhui Fuhuang Steel Structure Co Ltd
SHE:002743
|
-0.012x |
|
ACOTEC SCIEN.H. DL-00001
F:7W3
|
N/A |
|
FSP Technology Inc
TW:3015
|
0.012x |
Annual Cash Flow Conversion Efficiency for Amarin Corporation PLC (1993–2025)
The table below shows the annual cash flow conversion efficiency of Amarin Corporation PLC from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see AMRN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.28 Million | $6.74 Million | 0.015x | +123.01% |
| 2024-12-31 | $486.18 Million | $-31.02 Million | -0.064x | -610.03% |
| 2023-12-31 | $552.10 Million | $6.91 Million | 0.013x | +104.14% |
| 2022-12-31 | $595.33 Million | $-179.98 Million | -0.302x | -203.14% |
| 2021-12-31 | $667.10 Million | $-66.53 Million | -0.100x | -187.78% |
| 2020-12-31 | $627.50 Million | $-21.75 Million | -0.035x | -125.06% |
| 2019-12-31 | $608.26 Million | $-9.37 Million | -0.015x | +97.52% |
| 2018-12-31 | $152.33 Million | $-94.70 Million | -0.622x | -223.25% |
| 2017-12-31 | $-65.10 Million | $-32.84 Million | 0.504x | -93.64% |
| 2016-12-31 | $-9.06 Million | $-71.81 Million | 7.928x | +1108.61% |
| 2015-12-31 | $-129.19 Million | $-84.75 Million | 0.656x | -19.76% |
| 2014-12-31 | $-88.45 Million | $-72.31 Million | 0.818x | -85.46% |
| 2013-12-31 | $-33.86 Million | $-190.34 Million | 5.622x | -81.63% |
| 2012-12-31 | $-4.00 Million | $-122.30 Million | 30.599x | +362.56% |
| 2011-12-31 | $-5.96 Million | $-39.44 Million | 6.615x | +3852.38% |
| 2010-12-31 | $-202.37 Million | $-33.87 Million | 0.167x | +128.94% |
| 2009-12-31 | $48.60 Million | $-28.11 Million | -0.578x | +36.67% |
| 2008-12-31 | $28.90 Million | $-26.39 Million | -0.913x | +16.07% |
| 2007-12-31 | $24.15 Million | $-26.28 Million | -1.088x | -79.72% |
| 2006-12-31 | $37.84 Million | $-22.91 Million | -0.605x | -34.98% |
| 2005-12-31 | $38.58 Million | $-17.31 Million | -0.449x | +30.19% |
| 2004-12-31 | $16.69 Million | $-10.73 Million | -0.643x | -119.89% |
| 2003-12-31 | $-6.35 Million | $-20.50 Million | 3.230x | +459.06% |
| 2002-12-31 | $-6.21 Million | $5.59 Million | -0.900x | -257.77% |
| 2001-12-31 | $29.67 Million | $16.91 Million | 0.570x | +216.06% |
| 2000-12-31 | $31.17 Million | $5.62 Million | 0.180x | +123.07% |
| 1999-12-31 | $12.18 Million | $-9.53 Million | -0.782x | -270.26% |
| 1998-12-31 | $-13.50 Million | $-6.20 Million | 0.459x | +1787.78% |
| 1997-12-31 | $14.70 Million | $-400.00K | -0.027x | +94.80% |
| 1996-12-31 | $23.30 Million | $-12.20 Million | -0.524x | -415.25% |
| 1995-12-31 | $28.90 Million | $4.80 Million | 0.166x | +179.99% |
| 1993-12-31 | $18.30 Million | $-3.80 Million | -0.208x | -- |
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more